Novartis Unveils $30B In Deals To Drive Strategic Overhaul

Law360, New York (April 22, 2014, 12:01 PM EDT) -- Novartis AG on Tuesday unveiled several transactions worth nearly $30 billion combined that will dramatically reshape its operations, including the $16 billion acquisition of rival GlaxoSmithKline PLC's cancer drugs, making it the latest pharma giant to capitalize on a wave of deal-making in the sector.

The marquee piece of the restructuring is Novartis' purchase of GSK's oncology unit, one that it says will beef up its market-leading cancer products by folding in novel treatments and cementing its place as GSK's main commercialization partner for its robust...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.